(Q45865081)

17 December 2017

title

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus (English)

1 reference

17 December 2017

1 reference

1 reference

1 reference

2

1 reference

17 December 2017

Akseli Hemminki

14

object named as

Akseli Hemminki

1 reference

17 December 2017

7

Tanja Hakkarainen

1 reference

17 December 2017

13

David T Curiel

1 reference

17 December 2017

1

Anna Kanerva

1 reference

17 December 2017

Tandra R Chaudhuri

3

1 reference

17 December 2017

John T Lam

4

1 reference

17 December 2017

Kaori Suzuki

5

1 reference

17 December 2017

Taco G Uil

6

1 reference

17 December 2017

Gerd J Bauerschmitz

8

1 reference

17 December 2017

Minghui Wang

9

1 reference

17 December 2017

Bin Liu

10

1 reference

17 December 2017

Zhihong Cao

11

1 reference

17 December 2017

Ronald D Alvarez

12

1 reference

17 December 2017

publication date

1 September 2003

1 reference

17 December 2017

published in

Molecular Therapy

1 reference

17 December 2017

volume

8

1 reference

17 December 2017

page(s)

449-458

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

cites work

Adenoviral gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Adenoviruses in oncology: a viable option?

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

1 reference

7 January 2021

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Assays for noninvasive imaging of reporter gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob

1 reference

https://api.crossref.org/works/10.1016%2FS1525-0016%2803%2900200-4

7 January 2021

10.1016/S1525-0016(03)00200-4

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

12946318

1 reference

17 December 2017